Archana Asundi, MD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Infectious Diseases

MD, McGill University
BA, Tufts University

Pronouns: she/her/hers



Dr. Archana Asundi is a physician-scientist and infectious disease clinician, who specializes in care of people living with HIV with a specific focus on HIV and Aging. In her role Director of the Infectious Disease Clinical Research Unit (ID-CRU) at Boston Medical Center, she supports and oversees the conduct of a large portfolio of clinical trials and clinical-translational research studies in the Center for Infectious Disease (CID). Her individual research program focuses on investigating cardiometabolic comorbidities and weight gain/obesity among people living with HIV. She also engages in quality improvement and continuing medical education in the area of HIV and aging with several projects ongoing targeted around improvement of health-related quality of life among people aging with HIV.



HIV RNA modification and innate immune activation in HIV infection
07/08/2024 - 06/30/2029 (Subcontract PI)
PI: Archana Asundi, MD
Trustees of Boston University, BUMC NIH NIAID


GSK 3515864: A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single table
10/23/2023 - 10/23/2028 (PI)
ViiV Healthcare


GS-US-563-6041: A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV
04/06/2023 - 12/31/2027 (PI)
Gilead Sciences


GS-US-380-6738: A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV
12/01/2023 - 12/01/2027 (PI)
Gilead Sciences


GS-US-563-5925: A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)
11/22/2024 - 11/22/2027 (PI)
Gilead Sciences

GS-US-563-5926: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
11/20/2024 - 11/20/2027 (PI)
Gilead Sciences

TH-IBA-CTR-1003 PROMISE-US
10/27/2022 - 10/27/2025 (PI)
THERATECHNOLOGIES U.S., INC.


Is Integrase Inhibitor Emergent Weight Gain associated with increased Cardiometabolic Risk? A Nationwide Cohort Analysis
01/24/2022 - 09/30/2025 (PI)
Gilead Sciences


Identifying Factors to Improve Dental and Mental Healthcare among People with HIV
09/22/2023 - 09/21/2025 (Subcontract PI)
PI: Archana Asundi, MD
Rhode Island Hospital NIH NIDCR
1R56DE032873-01

Special Projects of National Significance - Demonstration/Implementation Sites
08/01/2022 - 07/31/2025 (PI)
Health Resources and Services Administration/DHHS


Showing 10 of 13 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Website       Copy PMIDs To Clipboard

  1. Ramaswamy S, Akiyama H, Berrigan J, Quiñones-Molina AA, Olson AJ, Chen Y, Liang Y, Henderson AJ, Asundi A, Sagar M, Gummuluru S. The macrophage-intrinsic MDA5/IRF5 axis drives HIV-1 intron-containing RNA-induced inflammatory responses. J Clin Invest. 2025 Aug 15; 135(16).View Related Profiles. PMID: 40493408; PMCID: PMC12352897; DOI: 10.1172/JCI187663;
     
  2. Bean DJ, Liang YM, Avila F, He X, Asundi A, Sagar M. Endemic coronavirus infection is associated with SARS-CoV-2 Fc receptor-binding antibodies. J Virol. 2025 Jun 17; 99(6):e0055025.View Related Profiles. PMID: 40387363; PMCID: PMC12172460; DOI: 10.1128/jvi.00550-25;
     
  3. Pickering RT, Asundi A, Olson A, Soden K, Kuritzkes DR, Lin NH. Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir. Antivir Ther. 2025 Feb; 30(1):13596535251314571.View Related Profiles. PMID: 39953931
     
  4. Lilie T, Bouzy J, Asundi A, Taylor J, Roche S, Olson A, Coxen K, Corry H, Jordan H, Clayton K, Lin N, Tsibris A. HIV-1 latency reversal agent boosting is not limited by opioid use. JCI Insight. 2024 Nov 22; 9(22). PMID: 39470739; PMCID: PMC11601940; DOI: 10.1172/jci.insight.185480;
     
  5. Pihl RMF, Smith-Mahoney EL, Olson A, Yuen RR, Asundi A, Lin N, Belkina AC, Snyder-Cappione JE. Vd1 Effector and Vd2 ?d T-Cell Subsets Shift in Frequency and Are Linked to Plasma Inflammatory Markers During Antiretroviral Therapy-Suppressed HIV Infection. J Infect Dis. 2024 May 15; 229(5):1317-1327.View Related Profiles. PMID: 38390982; PMCID: PMC11095541; DOI: 10.1093/infdis/jiae091;
     
  6. Lilie T, Bouzy J, Asundi A, Taylor J, Roche S, Olson A, Coxen K, Corry H, Jordan H, Clayton K, Lin N, Tsibris A. Opioid use does not limit potent low-dose HIV-1 latency reversal agent boosting. medRxiv. 2023 Jun 03. PMID: 37398278; PMCID: PMC10312897; DOI: 10.1101/2023.05.26.23290576;
     
  7. Asundi A, Olson A, Jiang W, Varshney SP, White LF, Sagar M, Lin NH. Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus. AIDS Res Hum Retroviruses. 2022 03; 38(3):208-215.View Related Profiles. PMID: 34877881; PMCID: PMC8968841; DOI: 10.1089/aid.2021.0091;
     
  8. Asundi A, O'Leary C, Bhadelia N. Global COVID-19 vaccine inequity: The scope, the impact, and the challenges. Cell Host Microbe. 2021 07 14; 29(7):1036-1039.View Related Profiles. PMID: 34265241; PMCID: PMC8279498; DOI: 10.1016/j.chom.2021.06.007;
     
  9. Asundi A, Resnik J, Benedict PA, Shin M, Rani Elwy A, Branch-Elliman W. How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols. Open Forum Infect Dis. 2021 Apr; 8(4):ofab072.View Related Profiles. PMID: 33855102; PMCID: PMC8026152; DOI: 10.1093/ofid/ofab072;
     
  10. Asundi A, Stanislawski M, Mehta P, Mull HJ, Schweizer ML, Barón AE, Ho PM, Gupta K, Branch-Elliman W. Development and Validation of a Semi-Automated Surveillance Algorithm for Cardiac Device Infections: Insights from the VA CART program. Sci Rep. 2020 03 24; 10(1):5276.View Related Profiles. PMID: 32210289; PMCID: PMC7093485; DOI: 10.1038/s41598-020-62083-y;
     
Showing 10 of 18 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 18 publications over 9 distinct years, with a maximum of 4 publications in 2019

YearPublications
20111
20181
20194
20203
20212
20221
20231
20242
20253

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.

HIV pioneers are aging faster than normal, prompting new approaches to care

Boston Globe 1/15/2025

Flurry of New Research Explores Weight Gain on Integrase Inhibitors Among People Living With HIV

The Body Pro 10/27/2020
Contact for Mentoring:

617.414.5260
Download vCard

Asundi's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (136) concept(s)
_
Media Mentions
_
Co-Authors
See all (16) people
_
Similar People
See all (60) people
_
Same Department
Search Department